Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 12, Issue 12, Pages 1925-1937Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.12.12.1925
Keywords
angiogenesis; apoptosis; cancer; differentiation; growth inhibition; PPAR-gamma; TZDs
Categories
Ask authors/readers for more resources
Thiazolidinediones (TZDs) are synthetic ligands; that activate the nuclear receptor peroxisome proliferator-activated receptor-gamma (PPAR-gamma). These compounds are widely used in the treatment of Type 2 diabetes. TZDs have antitumour activity in a wide variety of experimental cancer models, in vitro and in vivo, by affecting the cell cycle, induction of cell differentiation and apoptosis as well as by inhibiting tumour angiogenesis. These effects are mediated through both PPAR-gamma-dependent and -independent pathways depending on concentration and tumour cell type. Angiogenesis inhibition mechanisms of TZDs include directly inhibiting endothelial cell proliferation and migration as well as decreasing tumour cell vascular endothelial growth factor production. Further studies suggest that TZDs may be effective in prevention of certain cancers and in the treatment of cancer as adjuvant therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available